Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Zephyr Endobronchial Valves Improve FEV1 and Quality of Life in Heterogenous Emphysema

McGrath, Christopher, MD; West, Frances M., MD; Zappetti, Dana, MD

doi: 10.1097/CPM.0000000000000303
Pulmonary Trends
Buy
SDC

Synopsis: In patients with severe heterogenous emphysema and little or no collateral ventilation in target lobes, Zephyr Endobronchial Valve treatment provides statistical and clinical benefits in lung function and quality of life compared with current standard of care therapies over a 12-month period.

Source: Criner GJ, Sue R, Wright S, et al. LIBERATE Study Group. A multicenter randomized controlled trial of Zephyr endobronchial valve treatment in heterogenous emphysema (LIBERATE). Am J Respir Crit Care Med 2018;198:1151–1164.

Disclosure: The authors declare that they have no conflicts of interest.

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.